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Abstract:  
Vascular endothelial growth factor (VEGF) represents one of the main factor involved not 
only in angiogenesis and vasculogenesis but also in neuritogenesis,  VEGF plays its function 
acting via different receptors: VEGF receptor1 (VEGFR-1), VEGF receptor2 (VEGFR-2), 
VEGF receptor3 (VEGFR-3) and co-receptors Neuropilin-1 (NRP1) and Neuropilin-2 
(NRP2). 
This study reports on the first in vivo analysis of the expression of VEGF and VEGF family 
molecules in peripheral nerve degeneration and regeneration: for this purpose, different model 
of nerve lesion in rat were adopted, the median nerve crush injury and the median nerve 
transaction followed or not by end-to end microsurgical repair. 
Results obtained by Real Time polymerase chain reaction showed that VEGF and VEGF 
family molecules are differentially expressed under regenerating and degenerating condition, 
furthermore,  in order to study the modulation and involvement of these factors in two 
different regenerative models, crush injury and end-to-end repair, protein expression analysis 
was evaluated. In addition, immunohistochemical analysis allowed to state a glial localization 
of VEGF and VEGFR-2 after peripheral nerve crush injury. 
Finally in vitro assay on Primary Schwann cells culture show that VEGF165 stimulation 
increases Schwann cells migration, a major process in the promotion of neurite outgrowth. 
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Introduction 
Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen that increases blood 
vessels permeability and promotes angiogenesis. For this reason VEGF is mainly expressed 
by endothelial cells but also by activated macrophages and during cancer pathogenesis (Berse, 
Brown et al. 1992). 
VEGF belongs to a family of homodimeric glycoproteins  structurally related  to the platelet-
derived growth factors (PDGF); in mammals, VEGF family consists of five members, VEGF-
A, B, C, D and placenta growth factor (PLGF).  
Through alternative RNA splicing, different VEGF-A isoforms are generated: VEGF121,145, 
165, 183, 189 and 206. VEGF121 is a freely diffusible molecule  that lacks the basic amino 
acid residues and does not bind the extracellular matrix (ECM), VEGF165 contains some 
basic residues and  it is partly diffusible while VEGF189 contains even more basic residues, 
showing a spatially restricted localization to the matrix around the VEGF-producing cell 
(Cohen, Gitay-Goren et al. 1995; Ruiz de Almodovar, Lambrechts et al. 2009; Grunewald, 
Prota et al. 2010). 
VEGF binds three tyrosine kinase receptor: VEGF receptor1 (VEGFR-1), VEGF receptor2 
(VEGFR-2), VEGF receptor3 (VEGFR-3) and also receptors of the neuropilin family, 
Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) considered co-receptor for VEGF (Neufeld, 
Cohen et al. 1999; Ferrara, Gerber et al. 2003; Takahashi and Shibuya 2005; Ruiz de 
Almodovar, Lambrechts et al. 2009; Rosenstein, Krum et al. 2010; Carmeliet and Ruiz de 
Almodovar 2013). 
Since the vascular and the nervous system show similar anatomical features and despite the 
main role of VEGF as a pro-angiogenetic factor, an increasing number of studies focus the 
attention on VEGF activity on different neural cell types and recent evidence shows a role for 
VEGF as a neurotrophic and neuroprotective factor for neurons and glial cells. In fact, VEGF 
stimulates the proliferation of neuronal precursors, increasing the BrdU labeling,  in in vitro 
and in vivo models of neurogenesis (Jin, Zhu et al. 2002). Yet, it supports the survival of 
mesencephalic neurons in explants cultures (Silverman, Krum et al. 1999). 
Furthermore it has been reported that VEGF administration enhances axonal outgrowth from 
dorsal root ganglia adult mice explants promoting the survival of neurons and satellite glial 
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cells (Sondell, Lundborg et al. 1999; Sondell, Lundborg et al. 1999; Hobson, Green et al. 
2000; Brockington, Lewis et al. 2004; Pereira Lopes, Lisboa et al. 2011). 
Evidence has also been provided that VEGF administration increases the functional recovery 
after peripheral nerve injury since it was shown that after end-to-end neurorraphy (ETE) and 
end-to-side neurorraphy (ETS) of transected muscolocutaneous rats nerves, plasmid VEGF 
transfection in the distal stumps resulted in a better axon regeneration in terms of fibers 
density, axons diameter and myelin sheath thickness of regenerated axons (Haninec, Kaiser et 
al. 2012). 
The aim of our work is to investigate the expression of VEGF, VEGF receptors and VEGF 
co-receptors after nerve injury and regeneration. In the present study we carried out a 
biomolecular and immunohistochemical analysis on rat median nerve experimental models. In 
particular three different nerve injuries models will be used (crush injury, end-to-end repair 
and degenerating nerve) in order to analyze mRNA expression and protein expression and 
localization. 
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Materials and methods 
Animals 
All experiments were carried out on adult female Wistar rats (Charles River Laboratories, 
Milan, Italy) weighing approximately 190-220g.  
 
Surgery 
All procedures were performed in accordance with the Ethics Committee and the European 
Communities Council Directive of 24 November 1986 (86/609/ EEC).  
Animal well-being assessment was carried out using careful animal surveillance to check for 
passive and active movement, auto-mutilation, skin ulcers, and joint contracture, especially 
during early post-operative times.  
Adequate measures were taken to minimize pain and discomfort taking into account human 
endpoints for animal suffering and distress. 
For mRNA expression a total of 48 rats were used and three different surgeries were applied: 
crush injury, end to-end repair and degenerating nerve.  
For the crush injury group (n=3), the median nerve of both forelimb were crushed with a non-
serrated clamp at mid-humerus level according to the procedure described (Ronchi, Raimondo 
et al. 2010). For the end-to-end repair (n=3), median nerve was bilaterally transected at the 
same position described for the crush injury, proximal and distal stumps were immediately 
sutured using 9/0 epineurial sutures. In the degenerating group, median nerve was bilaterally 
transected and unrepaired. 
For the animals belonging to the control groups (CTRL) nerve was exposed and the skin was 
closed immediately after (n=3).  
For protein analysis, only rats resulting from crush injury and end-to-end repair were used, 
whereas uninjured rats were used as control (see Total Protein Extraction and Western Blot 
Analysis section).  
For morphological evaluation (see Immunofluorescence section) a total of 6 animals were 
used,  n=3 for crush injury and n=3  for control groups.  
All surgical procedures were carried out under deep anaesthesia obtained with Tiletamine + 
Zolazepam (Zoletil) i.m. (3 mg/kg). 
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For mRNA and protein analysys, median nerves were harvested 1d, 3d, 7d, 15d and 30d after 
the different surgeries, for morphological analysis rats were sacrified 7 days after crush 
injury. 
RNA isolation, cDNA preparation. 
Samples were frozen at -80° C and processed for RNA extraction. Total RNA was extract 
with the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. 0.5 µg total 
RNA were subjected to a reverse transcriptase (RT) reaction in 25 µL reaction volume 
containing: 1X RT-Buffer (Fermentas); 0.1 µg/µL bovine serum albumin (BSA, Sigma); 
0.05% Triton X-100; 1 mM dNTPs; 7.5 µM random exanucleotide primers (Fermentas); 1 
U/µl RIBOlock (Fermentas) and 200 U RevertAid™ M-MuLV reverse transcriptase 
(Fermentas). The reaction was performed for 10 min at 25°C, 90 min at 42°C, 10 min at 
90°C. Control reaction “RT-” (without the enzyme RT) and “H2O”, without RNA, was also 
carried out. RNA concentration was quantified using the Nanodrop® ND-1000 
spectrophotometer (Celbio, Milano, Italy).  cDNA was stocked at -20°C until used as a 
template for the real-time RT-PCR analysis.  
Quantitative real-time polymerase chain reaction (qRT-PCR). 
cDNA was diluted 5 times before analyses and 1 µl was analyzed in a total volume of 10 µl 
using 1X SYBR Green Supermix (Applied Biosystems) and 300 nM forward and reverse 
primers. Quantitative real-time PCR analysis was performed using chemistry with the 
StepOne Sequence Detection System (Applied Biosystems), dissociation curves were 
routinely performed to check the presence of a single peak in agreement to the required 
amplicon. Reactions were performed in technical and biological triplicate. 
Data were analyzed by ΔΔCt relative quantification method normalizing to the housekeeping 
gene ANKRD (Ankyrin repeat domain 27) and RICTOR (RPTOR Indipendent Companion of 
MTOR) (Gambarotta, Ronchi et al. 2014).  
Primers were designed using ANNHYB software (http://www.bioinformatics.org/annhyb/) 
and synthesized by Invitrogen (Life Technologies Europe BV, Monza, Italy).  
Primers sequences are reported in Table1. Relative expression levels were calculated by 
(ΔΔCt) method. The normalized relative quantity (NRQ) was determined using the formula: 
NRQ = 2−(ΔΔCt). Results were expressed as mean + S.D. 
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Total Protein Extraction and Western Blot Analysis. 
Total proteins were extracted using TRIzol Reagent (Invitrogen) according to the 
manufacturer's instructions. Protein pellets were resuspended in boiling Laemli buffer (2.5% 
SDS, 0.125 M Tris-HCl pH6.8) and followed by 3 min at 100°C. Protein concentration was 
determined using the Bicinchoninic Acid assay kit (BCA, Sigma), and equal amounts of 
proteins (40 µg, denaturated at 100°C in 240 mM 2-mercaptoethanol and 18% glycerol) were 
loaded onto each lane, separated by SDS-PAGE, transferred to iBlot® Transfer Stacks 
nitrocellulose membrane using the iBlot® Dry blotting Transfer Device (Invitrogen). 
Primary antibody used were: mouse monoclonal anti-VEGF-A (1:500, ab171828 Abcam),  
rabbit polyclonal anti-VEGFR-1 (1:1000, #2893 Cell-Signalling Technology), rabbit 
polyclonal anti-VEGFR-2 (1:1000, #2479 Cell-Signalling Technology), rabbit polyclonal 
anti-NRP1 (1:1000, #3725 Cell-Signalling Technology), rabbit polyclonal anti-NRP2 
(1:1000, #3366 Cell-Signalling Technology), mouse monoclonal anti-β-actin (1:4000 #A5316 
Sigma).  
Secondary used antibodies were horse-radish peroxidase-linked anti-rabbit (#NA934), and 
anti-mouse (#NA931) both used 1:20000 (GE Healthcare Life Science, Europe). 
Immunoflurescence and confocal laser microscopy. 
Nerve samples were fixed by immediate immersion in 4% paraformaldehyde for 2 h, washed 
in a solution of 0.2% glycine in 0.1 M phosphate buffer (pH 7.2), and embedded in OCT. 
Specimens were cut 10µm thick by a Leica CM3050S cryostat (Leica Microsystems, Wetzlar, 
Germany). Sections were permeabilized, blocked [0.1% triton X-100, 10% normal goat serum 
(NGS)/0.1% NaN3, 1h] and processed for an immunohistochemical protocol. See Table 2 for 
the list of primary antibodies used. Samples were incubated overnight in primary antibody or 
in case of double-immunofluorescence experiments, in a mixture of primary antibody and 
visualized using a solution containing the appropriate secondary antibodies: goat anti-mouse 
IgG Alexa-Fluor-488-conjugated (1:200, Molecular Probes, Eugene, Oregon), CY3-
conjugated anti-rabbit IgG (dilution 1:400, Dako, Milano, Italy). Nuclei were stained with 
4,6-diamidino-2-phenylindole (DAPI, Sigma) diluted 1:1000 in PBS. 
The samples were finally mounted with a Dako fluorescent mounting medium (DAKO) and 
analyzed by a LSM 510 confocal laser microscopy system (Zeiss, Jena, Germany).  
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Primary Schwann Cells (SC) Cultures. 
Primary Schwann cells (SC) cultures were obtained from fresh adult rat sciatic nerves. 
The sciatic nerves were collected and immediately kept in cold DMEM plus glutamax 
(Invitrogen, UK) containing 100 U/mL penicillin and 100 g/mL streptomycin. Nerves were 
dissected and the epineurium was stripped off. Nerve fragments were plated in a Petri dish in 
SC growth medium (DMEM plus glutamax containing 100U/mL penicillin, 100 g/mL 
streptomycin, 14 M forskolin, and 100 ng/mLNRG11, R&D Systems, UK) and incubated for 
2 weeks at 37∘C with fresh medium added approximately every 72h.  
Nerve fragments were incubated with 0.125% (w/v) collagenase type IV and 117 u/mg 
dispase for 24 hours and mechanically dissociated using a sterile Pasteur glass pipette in order 
to obtain a cell suspension. Cell suspension was filtered using a 70µm cell strainer (Falcon; 
BD Biosciences Discovery Labware, Bedford, MA) and centrifuged at 100×g for 5min to 
obtain the cell pellet. Finally, the cell pellet was resuspended in SC growth medium, seeded 
into a Petri dish pre-coated with poly-D-lysine (Sigma, St Louis, MO, USA), and incubated in 
the same conditions. SC were purified by an antibody complement method to roll out the 
remaining fibroblasts (Tohill, Mann et al. 2004; Kaewkhaw, Scutt et al. 2012; Pascal, 
Giovannelli et al. 2014) 
 
Proliferation Assay. 
Primary Schwann cells were seeded at a concentration of 1000 cells/cm2 on poly-D-lysine 
coverslips in complete DMEM containing 2%FBS as the control condition, or medium added 
with VEGF (50 ng/ml) (human VEGF-A165, R&D). After 1, 3, and 7 days, cells were fixed, 
stained, photographed and counted.  
Culture medium was removed, substrates with attached cells were rinsed with PBS with Ca2+ 
and Mg2+ and fixed by the addition of 4% paraformaldehyde solution. After 20 min, samples 
were rinsed with PBS with Ca2+ and Mg2 + and then stained with 4, 6-diamidino-2-
phenylindole (DAPI) diluted 1:1000 in PBS. Cells were photographed using an optical video-
confocal microscope (Nikon Eclipse 80i) and the supporting software Image ProPlus (Media 
Cybernetics USA). For each sample, four images were taken with at low magnification. The 
number of proliferated cells were counted by using Image J Software. All conditions were 
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performed in triplicate. The counts obtained from assays were analyzed, averaged, and 
expressed as the number of proliferated cell number/mm2 ± standard deviation.  
 
Three-dimensional migration: transwell assay.  
The Transwell migration assay was used to measure three-dimensional movement. Primary 
Schwann Cells (105) resuspended in 200 μl of DMEM containing 2% FBS were seeded in the 
upper chamber of a Transwell (cell culture insert, no. 353097, BD Biosciences) on a porous 
transparent polyethylene terephthalate membrane (8.0-μm pore size, 1 × 105 pores/cm2). The 
lower chamber (a 24-well plate well) was filled with DMEM containing 2% FBS with or 
without VEGF165 (50 ng/ml, R&D). The 24-well plates containing cell culture inserts were 
incubated at 33°C in a 5% CO2 atmosphere saturated with H2O. After 18 h of incubation, cells 
attached to the upper side of the membrane were mechanically removed using a cotton-tipped 
applicator. Cells that migrated to the lower side of the membrane were rinsed with PBS, fixed 
with 2% glutaraldehyde in PBS for 15 min at room temperature, washed five times with 
water, stained with 0.1% crystal violet and 20% methanol for 20 min at room temperature, 
washed five times with water, air-dried, and photographed using a Nikon ECLIPSE TS100 
inverted microscope equipped with a Nikon Digital Sight DSL1 camera; the images were 
analysed with ImageJ software. The experiments were repeated three times independently 
(biological triplicate). Each set included three control condition transwells and three 
transwells stimulated with VEGF165. Cell counts were expressed as percentage of migrated 
cells/total number of cells ± standard deviation. All conditions were performed three times 
independently (technical triplicate). Five images were analyzed for each transwell using the 
ImageJ software. Cell counts were expressed as percentage of migrated cells/total number of 
cells ± standard deviation.  
Statistical analysis. 
For in vivo experiments, statistical analysis was performed using one-way analysis of variance 
(ANOVA) and post hoc LSD. Two-way analysis of variance (ANOVA) and post-hoc 
Bonferroni was performed using the Prism Software Package (GraphPad, La Jolla, CA, USA) 
and SPSS.  For in vitro proliferation experiments, statistical analysis was performed using 
one-way analysis of variance (ANOVA) and post-hoc Bonferroni using the Prism Software.  
For in vitro migration assay, statistical analysis was performed using Two-Sample t-Test. The 
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level of significance was set at p ≤ 0.05 (*), p ≤ 0.01 (**), and p≤ 0.001 (***). Values are 
expressed as mean ± standard deviation (SD). 
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Results 
The expression of VEGF, VEGFR-1, VEGFR-2, VEGFR-3, NRP1 and NRP2 mRNAs were 
assessed in crush injury, end-to-end repair and degenerating conditions. 
The relative quantification (RQ) was determined using the control sample that better 
represents the mean of the control samples Ct; therefore, the relative (and not absolute) gene 
expression shown in the graphs cannot be compared among different genes. 
 
VEGF mRNA expression is differentially regulated in regenerating and degenerating 
condition. 
VEGF mRNA expression significantly increases in crush group at day 1 (p ≤ 0.01 (**)), day 3 
(p ≤ 0.05 (*)) and day 7 (p ≤ 0.01 (**)) after injury.  Whereas VEGF mRNA expression is 
significantly down regulated in degenerating condition at day 3(p ≤ 0.05 (*)), day 7 (p ≤ 0.01 
(**)) and day 30 (p ≤ 0.05 (*)). In end-to-end repair group  no significant differences are 
observed (Figure1).  
 
VEGFR-1 is strongly upregulated after crush injury.  
In crush injury group the mRNA level of VEGFR-1 is significantly upregulated peaking at 
day 1 after injury (p ≤ 0.001 (***)). The expression significantly decreases starting from day 
3 (p ≤ 0.05 (*)) and a significant downregulation is also detectable at day 30. In the end-to-
end repair and degenerating condition, mRNA expression of VEGFR-1 does not show 
significant variations (Figure 2). 
 
VEGFR-2 mRNA expression is strongly down regulated in regenerating and degenerating 
condition.  
Results on mRNA expression of VEGFR-2 in crush injury group showed that expression is 
significantly decreased 30 days after crush injury (p ≤ 0.05 (*)). In the end-to-end repair 
group a significant down regulation of VEGFR-2 is detectable at day 1 (p ≤ 0.05 (*)) and 30 
(p ≤ 0.05 (*)) after surgery.  
VEGFR-2 mRNA expression goes back to control condition level from day 3 up to day 7. 
Under degenerating condition mRNA VEGFR-2 expression levels did not change compared 
to control condition (Figure 3).   
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VEGFR-3 mRNA expression decreases in regenerating and degenerating condition.  
mRNA expression of VEGFR-3 significantly decreases starting from day 1 (p ≤ 0.01 (**)) in 
crush injury group. Decrement is also detectable at day 3 (p ≤ 0.01 (**)), day 7 (p ≤ 0.01 (**)) 
day 15 (p ≤ 0.001 (***)) lasting until day 30 (p ≤ 0.001 (***)) after injury. In degenerating 
nerve and end-to-end repair groups no regulation occurs (Figure 4). 
 
VEGF co-receptors NRP1 and NRP2 are significantly upregulated in degenerating condition. 
The mRNA expression of VEGF co-receptors NRP1 and NRP2 are both upregulated under 
degenerating condition. NRP1 is significantly upregulated (p ≤ 0.05 (*)) at day 3 and 15 (p ≤ 
0.05 (*)) and a higher upregulation is detectable at day 30 (p ≤ 0.01 (**)) in degenerating 
nerve.  The mRNA expression of NRP2 in degenerating condition is strongly upregulated 30 
days after injury (p ≤ 0.05 (*)) (Figure 5). 
 
Comparison between surgery: two-way ANOVA analysis 
Through two-way ANOVA analysis several relevant mRNA expression changes have been 
detected. The most relevant data to us is the VEGFR-3 expression since it is involved in 
inflammatory response. Its mRNA expression in degenerating nerve is higher compared to 
degenerating control condition, end-to-end repair and crush injury p-value ranging from p ≤ 
0.05 (*) to p ≤ 0.01 (***). (See Figure 6 for details). 
 
VEGF, VEGFR-2, NRP1 and NRP2 proteins are differentially expressed after crush injury. 
In order to focus the attention on nerve regeneration process, western blot analysis was 
performed only on crush injury and end-to-end repair group to confirm protein expression of 
some of genes analyzed by qRT-PCR. 
Western blot analysis showed that VEGF expression is detectable in both crush and end-to-
end nerves. The 43-kDa band is strongly detectable in control condition, 1 day, 3 days and 
day 7 after crush injury while a weak band is detectable at day 15 and 30 after injury. In end-
to-end nerves a high VEGF protein expression is observed in all time points post repair.  
Interestingly VEGFR-2 protein appears in end-to-end nerves starting from day 3 until 30 
days. In crushed nerves, high protein expression is found between day 1 and 15 after injury. 
No band appears in healthy nerves.  
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NRP1 antibody detects endogenous levels of total NRP1 protein through a 120-kDa band. 
This antibody also recognizes an 80-kDa protein of unknown origin.                     
Protein expression of NRP1 results with a very small band detectable in healthy control 
nerves although protein expression level increases in crushed nerves starting from day 1 until 
day 7 and then decreases until day 30. However the expression is higher compared to control 
condition. In end-to-end-nerves NRP1 protein expression is higher between day 3 and day 30.                             
Finally, NRP2 antibody detects endogenous levels of total NRP2 protein recognizing a 130-
kDa band. The protein expression level of NRP2 is barely detectable especially in crushed 
nerves in which a weak band appears starting from day 7 up to day 30 after injury. In end-to-
end repair group protein expression of NRP2 appears between day 1 and day 15 with a 
stronger band detectable at day 3 after surgery (Figure 7). 
 
VEGF, VEGFR-2 have a glial localization. 
Since Real Time PCR and western blot analysis do not allow to obtain a morphological 
evaluation, different immunohistochemical reactions were carried out using VEGF, VEGFR- 
2, NRP1 and NRP2 as markers. In order to study the localization of the different markers, 
double immunostaining with glial marker (S-100B) and neuronal marker (β-tubulin) were 
performed on crushed nerves. The employment of the crush injury, which interrupts nerve 
fibers without severing the connective tissue of the nerve trunk represents a suitable model for 
the study of the regenerative process providing an optimal regeneration pathway. Furthermore 
the crush lesion was applied  using a standardized and reproducible method, in terms of force, 
pressure and duration of the compression represented by the use of the not-serrate clump 
(Ronchi, Nicolino et al. 2009).  For this reason,  transversal sections of 10 µm of thickness 
were used to perform immunofluorescence staining only on crushed nerves harvested 7days 
after injury.  
According to Western blot analysis an immunoreactivity for VEGF was found around axons 
of healthy control nerves (Figure 8A). 
Interesting, the same VEGF immunoreactivity was found in nerves 7 days after crush injury, 
suggesting a glial expression of this marker  (Figure 8A-B). 
Immunofluorescence analysis was performed with other markers, VEGFR-2, NRP1, NRP2. 
As shown in Figure 8C, double immunostaining for VEGFR-2 and β-tubulin that represent a 
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typical neuronal marker showed absence of co-localization of these markers suggesting a glial 
expression of VEGFR-2.  
Finally, a double labeling for NRP1/β-tubulin and NRP2/β-tubulin was performed in order to 
identify co-receptors localization. A co-localization of NRP1 and β-tubulin was detected at 
nerve axons level (Figure 8D); absence of co-localization was found in case of double 
labeling NRP1/S-100b (Figure 8E). Co-localization of NRP2 and β-tubulin suggest the same 
expression pattern found for NRP1 (Figure 8F) with an axonal expression of NPR2.  
 
Administration of VEGF165 do not increase Primary Schwann cells proliferation. 
Proliferation assay was performed on Primary Schwann cells (SC) cultures seeded in 
complete DMEM containing 2%FBS as control condition, or in complete DMEM containing 
2%FBS added with VEGF165 (50 ng/ml) (human VEGF-A165, R&D). The number of 
proliferating cells was then counted quantifying the number of fluorescence labeled nuclei at 
different time points 1, 2 and 3 DIV after seeding. Schwann cells seeded with complete 
DMEM containing 2%FBS added with VEGF165 showed a proliferation rate comparable to 
control conditions, no significant differences have been observed between the two different 
conditions(Figure 9). Therefore, primary Schwann cell stimulation with VEGF165 did not 
affect cell proliferation. 
Three-dimensional migration assay on Primary Schwann cells culture showed a higher 
migration rate after VEGF165 stimulation. 
To determine whether VEGF165 stimulation on Primary Schwann cell cultures increases the 
migration of these cells a three-dimensional migration assay was performed.   
Primary Schwann cells (105) were seeded in the upper chamber of a transwell. In the lower 
chamber DMEM containing 2% FBS was supplemented with 50 ng/ml of VEGF165 as 
treatment (see three-dimensional migration: transwell assay section for details).  
After 18 h of incubation Primary Schwann cells added with 50 ng/ml of VEGF165 showed a 
significant higher migration rate (p ≤ 0.05 (*)) compared to Primary Schwann cells cultured 
in DMEM-2% FBS (Figure 10). 
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Discussion 
Peripheral nerve injury represents a very complex process that involves different 
morphological and molecular changes occurring to both proximal and distal stumps (Geuna, 
Raimondo et al. 2009; Allodi, Udina et al. 2012; Muratori, Ronchi et al. 2012).  
After injury, axons distal to regeneration site are interrupted, myelin sheath is degradated and 
Wallerian degeneration occurs leading to a series of phenotypic changes that promote axonal 
regeneration. It is well accepted that during the regenerative process various molecular factors 
are involved in order to form a favorable microenvironment for axonal outgrowth (Navarro, 
Vivo et al. 2007). 
For this reason, various molecules have been investigated in experimental models of neural 
repair in order to study promising strategies to improve very important aspects of the 
regenerative process such as axonal regrowth and target reinnervation (Raimondo, Fornaro et 
al. 2011; Kang, Kim et al. 2014; Chang, Quan et al. 2016).  
 
Vascular and nervous systems share common molecular pathways during development and 
regeneration, furthermore the anatomical parallelism between vessel and nerve patterning is 
well documented (Ruiz de Almodovar, Lambrechts et al. 2009).  
Anatomically, both systems are composed of afferent and efferent networks, arteries and 
veins, motor and sensory nerves and share similar patterning, with vessels running in parallel 
alongside nerve fibers as a mutual guidance alignment. 
Furthermore evidences show that axon guidance and vessel navigation are regulated by 
similar classes of molecules (Slits, Semaphorins, Netrins,and Ephrins) (Carmeliet and 
Tessier-Lavigne 2005; Carmeliet and Ruiz de Almodovar 2013).  
 
Even if it was demonstrated that VEGF plays a role during the development of the Central 
Nervous System (CNS), little is known about its presence and role in Peripheral Nervous 
System (PNS) (Rosenstein, Krum et al. 2010). This study focuses the attention on VEGF and 
its receptors and co-receptors expression in three different surgical models used to study 
peripheral nerve regeneration: the crush injury and the end-to-end repair represent  
regenerating conditions, while complete nerve transaction reflects a condition in which no 
signs of axonal regrowth are found (Ronchi, Haastert-Talini et al. 2016). 
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mRNA expression level for VEGFR-3 after crush injury showed a very low expression in all 
time points examined compared to control condition. Concerning end-to-end and 
degenerating nerve, no mRNA expression difference is detectable in all time points. This is 
probably due, as well reported, to restricted expression of the VEGFR-3 for lymphatic 
epithelium  (Kaipainen, Korhonen et al. 1995; Jussila and Alitalo 2002; Le Bras, 
Chatzopoulou et al. 2005). However if we consider the two-way ANOVA comparison, we 
observed higher VEGFR-3 expression from day 1 until day 30 in degenerating condition 
compared to crush and end-to-end repair. Crush and end-to-end represents regenerative 
models, so the immune response may be slow down from day 1 up to 30. In degenerating 
condition there is no regeneration thus the inflammatory condition may persists over time. 
This can explain why the VEGFR-3 expression is maintained at high level. 
NRP1 and NRP2 are a single pass transmembrane glycoproteins, originally identified as 
semaphorin receptors mediating axon growth cone collapse. Although, many study reported 
that NRP1 is involved in neuronal migration, dendritic guidance and repair of the adult 
nervous system (He, Wang et al. 2002). 
NRP2, can bind VEGF165 thus, in addition to neuronal guidance, plays a role in angiogenesis 
and cardiovascular functions (Favier, Alam et al. 2006). 
Our study showed that mRNA expression levels for NRP1 and 2 display a significant increase 
in degenerating condition. Since NRP1 and NRP2 are involved in several regenerative 
mechanisms as described above we suppose that in our degenerative model regeneration will 
not occur, explaining why their expression is manteined. 
mRNA and protein expression levels were evaluated by Real Time and western blot analysis 
respectively. NRP1 and NRP2 display similar mRNA and protein expression levels in both 
regenerative models (crush injury and end-to-end repair). Finally, double labeling for β-
tubulin/NRP1 and β-tubulin/NRP2 performed only on crush injury nerve, the surgical 
technique that provides clearest regeneration process, shows a co-localization for β-
tubulin/NRP1 and β-tubulin/ NRP2 allowing to state an axonal localization of these co-
receptors. 
VEGF mRNA expression is significantly upregulated during the early phases after peripheral 
nerve crush injury whereas a strong down-regulation occurs in degenerating nerve suggesting 
a possible role during the regenerative process.  
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Furthermore, mRNA expression levels of VEGFR-2, the most implicated in migration and 
survival of neural and glial cell types of both CNS and PNS (Sondell, Lundborg et al. 1999a; 
Sondell, Lundborg et al. 1999b; Jin, Mao et al. 2000; Jin, Zhu et al. 2002; Ogunshola, Antic et 
al. 2002), is highly expressed over time in crush injury; a significant decrease is detectable at 
30 days after injury allowing to suppose that the involvement of VEGFR-2 is restricted to the 
early phases of the regenerative process.  
In order to better characterize the expression of VEGF and VEGFR-2 under regenerating 
condition, protein expression levels were investigated after crush injury and end-to-end repair. 
Data obtained from western blot analysis showed a strong VEGF protein expression in control 
condition and following time points (1 day, 3 days and 7 days after crush injury). VEGF 
protein expression is also observed in end-to-end repair suggesting a similar expression 
pattern in the early phase of the regeneration process. Although further in vitro experiments 
need to be done in order to better characterize the molecular pathway involved in these 
mechanisms. 
Concerning VEGFR-2 protein results show that is expressed starting from day 3 until day 30 
in end-to-repair. To better characterize protein expression and localization, morphological 
analysis on crushed nerves were performed showing an intense immunoreactivity for VEGF 
around axons suggesting a glial expression of this marker.  
Furthermore, a double labelling for VEGFR-2 and β-tubulin show absence of co-localization 
between these two markers suggesting a glial expression also for VEGFR-2.  
Interestingly, data are supported by in vitro analysis on Primary Schwann cells cultures that 
significantly increases their migration after VEG165 stimulation compared to control 
condition suggesting a positive effect of VEGF on glial cells migration which represents a 
very important process during the peripheral nerve regeneration. 
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Conclusion 
Findings of the present study showed a modulation for VEGF and its family members 
including VEGFR-1, VEGFR-2, VEGFR-3, NRP1 and NRP2 under degenerating and 
regenerating conditions. Furthermore, morphological analysis allowed to understand the 
localization of the VEGF and the VEGFR-2 to Schwann cells after crush injury, used in this 
study as a suitable model for the study of the regenerative process (Ronchi, Nicolino et al. 
2009; Ronchi, Raimondo et al. 2010).  
Immunohistochemical results on VEGFR-2 showed also in this case a glial localization of this 
marker suggesting a potential autocrine VEGF/ VEGFR-2 pathway on Schwann cells. 
Morphological evaluation performed by immunofluorescence allowed to identify the glial 
localization for both factors. Furthermore in vitro experiments on primary Schwann cells 
culture let evaluate the effect of VEGF on the migratory property of the Schwann cells 
suggesting that VEGF could influence the migration of Schwann cells that represents an 
important step during the regeneration process. 
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Figure Legends 
Figure 1: VEGF mRNA expression significantly increases in crush group starting from day 1 
(p ≤ 0.01 (**)), day 3 (p ≤ 0.05 (*)) and day 7 (p ≤ 0.01 (**)) after injury.  A downregulation 
is detectable in degenerating condition at day 3(p ≤ 0.05 (*)), day 7 (p ≤ 0.01 (**)) and day 30 
(p ≤ 0.05 (*)). In end-to-end repair group a weak increase in VEGF mRNA expression level is 
detectable at day 30. N=3 in each time point condition. 
Figure 2: mRNA level of VEGFR1 is significantly upregulated in crush injury group the 
peaking at day 1 after injury (p ≤ 0.001 (***)). The expression significantly decreases starting 
from day 3 (p ≤ 0.05 (*)) and a significant downregulation is also detectable at day 30. In the 
end-to-end repair group mRNA expression of VEGFR-1 decrease at day 1, at day 3 
expression level increase while a strong reduction is detectable at day 30. VEGFR-1 mRNA 
expression level increase at day 1 and 3 decreasing gradually in degenerating nerve from day 
7. N=3 in each time point condition. 
Figure 3: mRNA expression of VEGFR-2 significantly decreased 30 days after crush injury 
(p ≤ 0.05 (*)).  In the End-to-end repair group a significant down regulation of VEGFR-2 is 
detectable at day 1 after surgery. mRNA expression of VEGFR-2 remains low from day 1 
after injury until day 30 with a very weak increase at day 30 in degenerating nerve. N=3 in 
each time point condition. 
Figure 4: mRNA expression of VEGFR-3 significantly decreases starting from day 1(p ≤ 
0.01 (**)) until day 30 (p ≤ 0.001 (***)) in crush injury group. In degenerating condition a 
strong down regulation occurs starting from day 1 until day 30. In end-to-end repair group 
mRNA expression of VEGFR-3 increases at day 1 and decreases from day 3 to day 30 after 
surgery. N=3 in each time point condition. 
Figure 5: Two-way analysis of variance (ANOVA) and post-hoc Bonferroni showed mRNA 
expression in degenerating nerve is higher compared to degenerating control condition, end-
to-end repair and crush injury p-value ranging from p ≤ 0.05 (*) to p ≤ 0.01 (***). 
Figure 6: NRP1 and NRP2 are significantly upregulated in degenerating condition. NRP1 is 
significantly upregulated (p ≤ 0.05 (*)) at day 3 and 15 (p ≤ 0.05 (*)) and a higher 
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upregulation is detectable at day 30 (p ≤ 0.01 (**)) in degenerating nerve.  The mRNA 
expression of NRP2 is strongly upregulated 30 days in degenerating condition (p ≤ 0.05 
(*)).N=3 in each time point condition. 
Figure 7: VEGF expression is detectable in both crush and end-to-end nerves. The band is 
strongly detectable in control condition, 1 day, 3 days, 7 days and 30 days after crush injury. 
In end-to-end nerves a high VEGF protein expression is observed in all day points post repair. 
VEGFR-2 band appears in end-to-end nerves starting from day 3 until 30 days. In crushed 
nerves high protein expression is found between day 1 and day 30 after injury. Protein 
expression of NRP1 results with a very small band detectable in control nerves although 
protein expression level increases in crushed nerves starting from day 1 until day 30. In end-
to-end-nerves NRP1 protein expression is higher between day 3 and day 30. Protein 
expression of NRP2 is barely detectable in crushed nerves; in end-to-end repair NRP2 appears 
between day 3 and day 30 after surgery. 
Figure 8: immunofluorescence staining for VEGF (red) in healthy control nerve (A) and 
crushed nerve 7 days after injury (B); double immunostaining for VEGFR-2 (red) and β-
tubulin (green) showed absence of co-localization of these markers (C). Co-localization of 
NRP1 (red) and β-tubulin (green) is detected at nerve axons level (D); absence of co-
localization is found in case of double labeling NRP1 (red) S-100b (green) (E). Co-
localization of NRP2 and β-tubulin suggest the same expression pattern of NRP1 (F). Scale 
bar =100 µm. Nuclei are stained with DAPI (blue). Panel A 63X, panel B-F 40X. 
Figure 9: Proliferation assay on Primary Schwann cell culture in control condition and 
after VEGF165 (50 ng/ml) stimulation. 
Figure 10: Three-dimensional migration assay on Primary Schwann cells culture in 
control condition (DMEM/ 2% FBS) and after stimulation with (50 ng/ml) of VEGF165. 
Data show a higher migration rate after VEGF165 stimulation (p ≤ 0.05 (*)). 
Table1: Primers used for qRT-PCR.  
Table2: Primary antibodies used for immunofluorescence. 
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